BioInvent is focused on developing novel immuno-modulatory antibodies for cancer therapy. BioInvent’s innovative antibodies may significantly improve the efficacy of currently available immuno-modulatory checkpoint inhibitor therapies and/or activate anti-cancer immunity in currently non-responding patients and cancer types.

Our publications
BioInvent's cutting-edge research is acknowledged through high quality scientific publications. The company's scientists have a documented track-record of being accepted for publication in high impact-factor publications.
Read more
BioInventEvents
Our events are hosted globally and online

BioInventInvestor
BioInvent is in a very attractive position with several value drivers
All pharmaceutical development is associated with risk. BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big pharma community, solid ownership and a strong cash position give BioInvent a solid platform to continue its transformation.